Insight Molecular Diagnostics Inc. (IMDX) stock
Close on Nov 12, 2026Market cap $75.59MP/E –Yield –
Insight Molecular Diagnostics Inc. saw revenue fall 60.8% to $1.67M over the twelve months to Jun 30, 2026. Free cash flow was -$31.00M. At the latest close the market valued the company at $75.59M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $75.59M
- P/E ratio
- –
- Price to sales
- 45.27
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -41.01%
Fundamentals
- Revenue
- $1.67M
- Net income
- -$49.36M
- EPS, diluted
- -$1.49
- Free cash flow
- -$31.00M
- Book value per share
- -$0.58
- Diluted shares
- 37M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $2.39
- Open
- $2.35
- Day's range
- $2.19 – $2.38
- Volume
- 143,637
- Average volume (20 days)
- 170,414
- Beta (5 years)
- 1.11
- 52-week range
- $2.19 – $8.51
- RSI (14 days)
- 29.0
- Volatility (1 year)
- 106.8%
- Relative volume
- 0.64×
- WACC
- 10.4%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMDX | S&P 500 | Difference | IMDX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -27.1% | -2.7% | −24.4 pts | ||
| 3 months | -48.7% | -1.7% | −46.9 pts | ||
| Year to date | -69.2% | +11.9% | −81.1 pts | ||
| 1 year | -72.8% | +12.0% | −84.7 pts | ||
| 3 years | -16.9% | +78.2% | −95.1 pts | -6.0% | +21.2% |
| 5 years | -96.3% | +73.2% | −169.5 pts | -48.3% | +11.6% |
| 10 years | -97.7% | +309.6% | −407.4 pts | -31.5% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Insight Molecular Diagnostics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Update
- Results
About Insight Molecular Diagnostics
In Vitro & In Vivo Diagnostic Substances
The company is a diagnostics technology developer focused on decentralized molecular testing kits, primarily for monitoring transplanted organ rejection. Its diagnostic portfolio features the GraftAssure family of assays, which quantify donor-derived cell-free DNA to assess graft organ health. These include a laboratory-developed test, a research-use-only test kit, and an in-vitro diagnostic kit under development. Additionally, the company maintains research-stage oncology programs and provides assay development and clinical testing services through its laboratory operations. Initial target customers comprise hospitals, transplant centers, research facilities, and local laboratories.
Company profile, executives and historyInsight Molecular Diagnostics stock: common questions
What is Insight Molecular Diagnostics's stock price?
IMDX closed at $2.31 on Nov 12, 2026, down 3.35% on the day. Over the past 52 weeks it traded between $2.19 and $8.51.
What is Insight Molecular Diagnostics's market cap?
Insight Molecular Diagnostics was worth $75.59M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IMDX's P/E ratio?
Insight Molecular Diagnostics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.49), so it has no meaningful P/E ratio.
How much revenue does Insight Molecular Diagnostics make?
Insight Molecular Diagnostics reported revenue of $1.67M for the twelve months to Jun 30, 2026, down 60.8% from a year earlier.
Does Insight Molecular Diagnostics pay a dividend?
No. Insight Molecular Diagnostics has not paid a cash dividend over the last twelve months.
When does Insight Molecular Diagnostics report earnings next?
Insight Molecular Diagnostics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has IMDX stock performed over the past year?
Including dividends, IMDX returned -72.8% over the past year, against +12.0% for the S&P 500.
How many IMDX shares are sold short?
1M shares were sold short at the latest FINRA report, 17.02% of the float, or 5.1 days of average trading volume.
Who are Insight Molecular Diagnostics's competitors?
Companies most similar to Insight Molecular Diagnostics by business, industry and size include BMRA, VNRX, NNNN, AWHL, SCNI.
See a number that looks wrong?